JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 9.31 Billion | -5.5 Billion | 9.28 Billion | 10.34 Billion | 4.92 Billion | 3.9 Billion |
| Net Income | 5.5 Billion | 5.41 Billion | 19.4 Billion | 8.65 Billion | 3.42 Billion | 4.92 Billion |
| Depreciation & Amortization | 3.19 Billion | 1.99 Billion | 1.94 Billion | 1.89 Billion | 1.43 Billion | 1.34 Billion |
| Deferred income taxes | - | -9.22 Billion | -3.07 Billion | -983 Million | -1.29 Billion | -1.31 Billion |
| Stock-based compensation | 71 Million | 173 Million | 177 Million | 149 Million | 175 Million | 144 Million |
| Change in working capital | -3.53 Billion | -2.95 Billion | -9.03 Billion | 323 Million | 1.39 Billion | -1.58 Billion |
| Other non-cash items | 17.03 Billion | -905 Million | -133 Million | 307 Million | -211 Million | 385 Million |
| Investing Cash Flow | -2.69 Billion | -15 Billion | -3.25 Billion | -3.29 Billion | -4.16 Billion | 240 Million |
| Investments in PPE | -2.09 Billion | -8.56 Billion | -11.33 Billion | -7.52 Billion | -4.83 Billion | -895 Million |
| Acquisitions | -600 Million | -6.71 Billion | 8.16 Billion | -2.74 Billion | - | - |
| Investment purchases | - | -906 Million | -300 Million | -391 Million | -30 Million | -100 Million |
| Sales/Maturities of investments | - | 259 Million | 300 Million | 584 Million | 798 Million | 1.25 Billion |
| Other Investing Activities | 5 Million | 922 Million | -84 Million | 6.79 Billion | -91 Million | -22 Million |
| Financing Cash Flow | -2.03 Billion | 1.94 Billion | -2.17 Billion | 8.3 Billion | 2.04 Billion | -917 Million |
| Debt repayment | -500 Million | -3.05 Billion | -750 Million | -650 Million | -850 Million | -413 Million |
| Dividends payments | -2.5 Billion | -2.73 Billion | -2.16 Billion | -1.08 Billion | -989 Million | -834 Million |
| Common Stock Repurchased | 15 Million | 10 Million | 10 Million | 13 Million | 15 Million | 26 Million |
| Common Stock Issuance | 15 Million | 7.72 Billion | 740 Million | 10.02 Billion | 3.87 Billion | 387 Million |
| Other Financing Activities | -46 Million | -1 Million | -10 Million | 1 Million | -2 Million | -83 Million |
| Accounts receivables | -3.39 Billion | 4.44 Billion | -7.4 Billion | -205 Million | 857 Million | -1.73 Billion |
| Accounts payables | -672 Million | 238 Million | -1.6 Billion | 2.25 Billion | 92 Million | - |
| Inventory | -2.43 Billion | -3.87 Billion | -1.08 Billion | -4.69 Billion | 258 Million | -157 Million |
| Other working capital | 2.96 Billion | -3.76 Billion | 1.06 Billion | 2.97 Billion | 191 Million | 304 Million |
| Cash at beginning of period | 13.27 Billion | 30.73 Billion | 26.26 Billion | 10.92 Billion | 8.09 Billion | 4.85 Billion |
| Cash at end of period | 18.75 Billion | 13.27 Billion | 30.73 Billion | 26.26 Billion | 10.92 Billion | 8.09 Billion |
| Capital Expenditure | -2.09 Billion | -8.56 Billion | -11.33 Billion | -7.52 Billion | -4.83 Billion | -895 Million |
| Effect of forex changes on cash | 886 Million | 1.09 Billion | 612 Million | -22 Million | 20 Million | 12 Million |
| Net cash flow / Change in cash | 5.47 Billion | -17.45 Billion | 4.47 Billion | 15.33 Billion | 2.83 Billion | 3.24 Billion |
| Free Cash Flow | 7.21 Billion | -14.06 Billion | -2.04 Billion | 2.81 Billion | 89 Million | 3.01 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 201 Million | 5.5 Billion | 347 Million | -93 Million | 3.64 Billion | 1.61 Billion |
| Depreciation & Amortization | - | 3.19 Billion | - | 936 Million | 824 Million | 511 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 71 Million | - | - | - | - |
| Change in working capital | - | -3.53 Billion | - | - | - | - |
| Other non-cash items | -201 Million | 17.03 Billion | -347 Million | 93 Million | -3.64 Billion | -1.61 Billion |
| Investing Cash Flow | - | -2.69 Billion | - | - | - | - |
| Investments in PPE | - | -2.09 Billion | - | - | - | - |
| Acquisitions | - | -600 Million | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 5 Million | - | - | - | - |
| Financing Cash Flow | - | -2.03 Billion | - | - | - | - |
| Debt repayment | - | -500 Million | - | - | - | - |
| Dividends payments | - | -2.5 Billion | - | - | - | - |
| Common Stock Repurchased | - | 15 Million | - | - | - | - |
| Common Stock Issuance | - | 15 Million | - | - | - | - |
| Other Financing Activities | - | -46 Million | - | - | - | - |
| Accounts receivables | - | -3.39 Billion | - | - | - | - |
| Accounts payables | - | -672 Million | - | - | - | - |
| Inventory | - | -2.43 Billion | - | - | - | - |
| Other working capital | - | 2.96 Billion | - | - | - | - |
| Cash at beginning of period | - | 13.27 Billion | - | 15.96 Billion | 15.33 Billion | 13.27 Billion |
| Cash at end of period | - | 18.75 Billion | - | 18.3 Billion | 15.96 Billion | 15.33 Billion |
| Capital Expenditure | - | -2.09 Billion | - | - | - | - |
| Effect of forex changes on cash | - | 886 Million | - | - | - | - |
| Net cash flow / Change in cash | - | 5.47 Billion | - | 2.33 Billion | 637 Million | 2.05 Billion |
| Free Cash Flow | - | 7.21 Billion | - | 1.87 Billion | 1.64 Billion | 1.02 Billion |
DARK
WINTW
9441
FTC
6582
0IP1